Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC). Results from the Phase III CheckMate 77T study were…
in Health
Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
